Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
Go back to Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 +0.70 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.00 | 52 Week High | $77.12 | |||
| Open | $54.20 | 52 Week Low | $49.03 | |||
| Day High | $54.73 | P/E | 35.52 | |||
| Day Low | $54.00 | EPS | $1.54 | |||
| Volume | 16,174,661 | |||||
